share_log

Biora Therapeutics Announces Successful Completion Of Device Performance Study In Ulcerative Colitis Patients For Its Targeted Therapeutics Platform

Benzinga Real-time News ·  Aug 10, 2022 09:04

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutics, today announced topline results from its recently completed study PM-602: A Scintigraphic Study to Evaluate the Localization and Delivery Function of a Drug Delivery System Capsule (DDS) in Subjects with Ulcerative Colitis in a Fasted State.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment